As we celebrate International Earth Day, this year's theme "Invest in our planet" takes on increased significance as the company released its first-ever ESG report for 2022 in March 2023. 

BGI Genomics is proud to be part of the global efforts to reduce carbon footprint, and fight climate change, while striving to leverage innovation in our Health For All mission. 

Carbon Footprint Management 

Every BGI Genomics' non-invasive prenatal test service only produces 3.6173kg of carbon dioxide, consistent with ISO14067:2018 carbon footprint standard.

Every product lineup includes detailed carbon footprint management. For example, every non-invasive prenatal test (NIPT) service only produces 3.6173kg of CO2, consistent with ISO14067:2018 carbon footprint standard.

Healthcare Innovation

From colorectal cancer detection upgrade to a new type of DNA & RNA test for leukemia, BGIers continuously challenge themselves to think outside the box.

Innovation is in our DNA and helps us commit to ESG standards as part of our mission to bring health for all. We continue our investments to enhance our colorectal cancer screening tests and carrier screening tests. In addition, we have launched a new RNA and DNA test for leukemia. 

About BGI Genomics

BGI Genomics, headquartered in Shenzhen China, is the world's leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.